{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:37:16Z","timestamp":1794893836195,"version":"4.9.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness\/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12\/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25\/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP &amp;gt; 2 or improvement &amp;gt; 85% in DAPSA) was achieved in 69.4% of patients (n=25\/36 therapeutical combinations; 17\/21 SpA, 8\/15 PsA), with a 58.3% (n=21\/36 combinations; 15\/20 SpA, 6\/13 PsA) low-activity\/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1283251","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T17:12:25Z","timestamp":1698081145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain"],"prefix":"10.3389","volume":"14","author":[{"given":"Cristina","family":"Valero-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit Font","family":"Urgelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Sall\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz E.","family":"Joven-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"de Juanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Juanola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Almod\u00f3var","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Laiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Pinto-Tasende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cresp\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Sala-Icardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00984-8","article-title":"Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies. Nature reviews","volume":"19","author":"Cozzi","year":"2023","journal-title":"Rheumatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10494","article-title":"Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis","volume":"14","author":"Furer","year":"2023","journal-title":"Rambam Maimonides Med J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105578","article-title":"Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis","volume":"90","author":"Mutlu","year":"2023","journal-title":"Joint Bone spine."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: A systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2022.2045350","article-title":"Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study","volume":"57","author":"Eronen","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1597159","article-title":"Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis","volume":"54","author":"Ribaldone","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-alpha and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: A long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key199","article-title":"Combined inhibition of tumour necrosis factor-alpha and interleukin-12\/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways","volume":"57","author":"De Marco","year":"2018","journal-title":"Rheumatology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2021-221812","article-title":"Effectiveness and safety of combined biological therapy in patients with refractory multidomain spondyloarthritis","volume":"81","author":"Valero","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152237","article-title":"Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs\/tsDMARDs and potential barriers","volume":"62","author":"Ortolan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10067-017-3953-6","article-title":"Effectiveness and safety of ustekinumab in na\u00efve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study","volume":"37","author":"Chimenti","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.035","article-title":"Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study","volume":"16","author":"Sands","year":"2022","journal-title":"J Crohns Colitis."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3899\/jrheum.120924","article-title":"Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study","volume":"40","author":"Rigby","year":"2013","journal-title":"J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000663","article-title":"A case series on patients on tofacitinib in combination with a biologic","volume":"24","author":"Barroso","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report","volume":"1","author":"Babalola","year":"2014","journal-title":"JAAD Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa880","article-title":"Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination","volume":"60","author":"Haberman","year":"2021","journal-title":"Rheumatol (Oxford)."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13752","article-title":"Novel combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis in a medically complex patient","volume":"63","author":"Hanna","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B30","article-title":"Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: A case report","volume":"18","author":"Rathod","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001767","article-title":"Combination therapy with tofacitinib and IL-12\/23, IL-23, or IL-17A inhibition for the treatment of refractory psoriatic arthritis: A case series","volume":"28","author":"Shurey","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2174\/1573397115666181130094455","article-title":"Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis","volume":"15","author":"Metyas","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00703-1","article-title":"Combination therapy with apremilast and biologics for psoriasis: A systematic review","volume":"23","author":"Gyldenl\u00f8ve","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2018-000243","article-title":"Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics","volume":"5","author":"Mao","year":"2018","journal-title":"BMJ Open gastroenterology."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2016-000127","article-title":"Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis","volume":"4","author":"Bethge","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.242","article-title":"Long-term combination therapy with anti-TNF plus vedolizumab induces and maintains remission in therapy-refractory ulcerative colitis","volume":"112","author":"Fischer","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx142","article-title":"Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy","volume":"12","author":"Roblin","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa149","article-title":"Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease","volume":"15","author":"Privitera","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15891","article-title":"Letter: combination of biologics in inflammatory bowel diseases","volume":"52","author":"Fumery","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000613016.81984.79","article-title":"P012 successful use of combination biologic therapy in medically refractory pediatric crohn's disease and sacroiliitis","volume":"114","author":"Bass","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(19)39173-5","article-title":"Mo1906 \u2013 combination therapy of vedolizumab and tofacitinib in IBD patients with chronic active refractory disease course and spondylarthritis","volume":"156","author":"Kuehbacher","year":"2019","journal-title":"Gastroenterology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000597696.98363.85","article-title":"Successful treatment of ulcerative colitis and seronegative inflammatory spondyloarthritis using concomitant vedolizumab and tofacitinib: A case report","volume":"114","author":"Lee","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212819","article-title":"Simultaneous inhibition of \u03b14\/\u03b27 integrin and tumour necrosis factor-\u03b1 in concomitant spondyloarthritis and inflammatory bowel disease","volume":"77","author":"Richard","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000226","article-title":"Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis","volume":"6","author":"Wang","year":"2019","journal-title":"ACG Case Rep J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16120","article-title":"Combination non tumour necrosis factor biologic and small-molecule therapy in a patient with ankylosing spondylitis and Crohn disease","volume":"53","author":"Li","year":"2023","journal-title":"Intern Med J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020859","article-title":"Dual blockade of TNF and IL-17A inhibits inflammation and structural damage in a rat model of spondyloarthritis","volume":"23","author":"Hammoura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801436","article-title":"Combined blockade of TNF-\u03b1 and IL-17A alleviates progression of collagen-induced arthritis without causing serious infections in mice","volume":"202","author":"Shen","year":"2019","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkad018","article-title":"Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series","volume":"7","author":"Malik","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"B53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5152\/EuJRheum.2022.21180","article-title":"Dual biologic therapy in patients with familial mediterranean fever and spondyloarthritis: case-based review","volume":"10","author":"Y\u0131ld\u0131r\u0131m","year":"2023","journal-title":"Eur J Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13498","article-title":"Long-term safety of combined biological therapy in a patient affected by arthropathic psoriasis and atopic dermatitis","volume":"33","author":"Balestri","year":"2020","journal-title":"Dermatol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2020.21162","article-title":"Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases","volume":"8","author":"Bruni","year":"2021","journal-title":"Eur J Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1283251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T17:12:29Z","timestamp":1698081149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1283251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2023.1283251"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1283251","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"article-number":"1283251"}}